OSI Board Rejects Astellas, Seeks Other Bids
This article was originally published in PharmAsia News
Executive Summary
OSI Pharmaceuticals told its shareholders on March 15 to reject Astellas Pharma's hostile $3.5 billion buyout offer, arguing that Astellas's bid ignores the value of OSI's cash and pipeline